way 100135 has been researched along with sarizotan in 1 studies
| Studies (way 100135) | Trials (way 100135) | Recent Studies (post-2010) (way 100135) | Studies (sarizotan) | Trials (sarizotan) | Recent Studies (post-2010) (sarizotan) |
|---|---|---|---|---|---|
| 143 | 0 | 34 | 26 | 7 | 5 |
| Protein | Taxonomy | way 100135 (IC50) | sarizotan (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | 0.006 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.006 | |
| D(4) dopamine receptor | Homo sapiens (human) | 0.006 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.006 | |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | 0.006 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antonelli, T; Bartoszyk, GD; Ferraro, L; Fuxe, K; Seyfried, CA; Tanganelli, S; Tomasini, MC | 1 |
1 other study(ies) available for way 100135 and sarizotan
| Article | Year |
|---|---|
Effects of sarizotan on the corticostriatal glutamate pathways.
Topics: Animals; Antiparkinson Agents; Down-Regulation; Dyskinesias; Extracellular Fluid; Glutamic Acid; Male; Microdialysis; Motor Cortex; Neostriatum; Neural Inhibition; Neural Pathways; Organic Chemicals; Piperazines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Synaptic Transmission | 2005 |